Anest Iwata board evaluation finds continuous improvement, identifies key areas

Anest Iwata Corporation announced the results of its annual Board of Directors effectiveness evaluation for the fiscal year 2024, confirming continuous improvements. The evaluation, conducted in April 2025 through a third-party survey with revised questions, assessed 14 board meetings held from April 2024 to March 2025. All nine directors participated, reviewing aspects such as board structure, management strategy, risk management, nomination and remuneration, and stakeholder communication. Discussions and opinion exchanges among directors took place from June to August 2025.

The analysis concluded that the board is "sufficiently effective," with directors fulfilling their roles, enhancing information exchange, and conducting open meetings. However, the evaluation identified key areas for further improvement: re-evaluating the board's nature, discussing management personnel training and retention, and enhancing communication between independent directors and shareholders. These points will be prioritized for in-depth discussions at opinion exchange meetings.

The company also acknowledged ongoing issues from previous years, including the systematic implementation of education and training for executive directors and future management candidates. While progress was made in addressing issues related to director remuneration and optimizing deliberation schedules and materials, the board will continue discussions on enhancing systems and operations for independent directors and the Audit and Supervisory Committee.